The role of cathepsins in osteoporosis and arthritis: Rationale for the design of new therapeutics

Advanced Drug Delivery Reviews

Volumn 57, Issue 7, 2005, Pages 973-993

  Yasuda, Yoshiyuki ^a   Kaleta, Jadwiga ^b   Brömme, Dieter ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b NAEJA Pharmaceuticals Inc   (Canada)

Author keywords

Arthritis; Cathepsin K; Cathepsin S; Cysteine protease inhibitors; Cysteine proteases; Osteoporosis

Indexed keywords

BODY FLUIDS; DRUG PRODUCTS; ENZYMES; IMMUNOLOGY; MUSCULOSKELETAL SYSTEM;

ARTHRITIS; CATHEPSINS; MUSCULOSKELETAL DISEASES; OSTEOPOROSIS;

DISEASES;

ACETYLSALICYLIC ACID; ALENDRONIC ACID; AURANOFIN; AUROTHIOMALATE; AZATHIOPRINE; BALICATIB; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; CATHEPSIN K; CATHEPSIN S; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; CYCLOSPORIN A; ESTROGEN; ETANERCEPT; GESTAGEN; HYDROXYCHLOROQUINE; IBUPROFEN; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; MV 57471; NONSTEROID ANTIINFLAMMATORY AGENT; PARATHYROID HORMONE; PENICILLAMINE; RALOXIFENE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RISEDRONIC ACID; ROFECOXIB; SALAZOSULFAPYRIDINE; SB 331750; SB 357114; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITAMIN D;

AGITATION; ALLERGIC ASTHMA; ANOREXIA; ARTHRITIS; ASTHMA; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; BLEEDING; BLOATING; BLOOD DISEASE; BONE DISEASE; BONE NECROSIS; BREAST CANCER; BREAST TENDERNESS; CANCER; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONFUSION; CONSTIPATION; DEPRESSION; DIZZINESS; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FATIGUE; GASTROINTESTINAL DISEASE; GINGIVA OVERGROWTH; GRAFT REJECTION; HAIR LOSS; HEADACHE; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; HYPERTENSION; INDIGESTION; INFECTION; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; LEG CRAMP; LEUKEMIA; LIVER DISEASE; MENOPAUSAL SYNDROME; MOUTH DISEASE; MOUTH ULCER; MULTIPLE SCLEROSIS; MYALGIA; NAUSEA; NONHUMAN; NOSE CONGESTION; OSTEOARTHRITIS; OSTEOPOROSIS; PRIORITY JOURNAL; RASH; RESPIRATORY TRACT DISEASE; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SORE THROAT; STOMACH PAIN; STOMACH ULCER; STROKE; THORAX PAIN; TINNITUS; VEIN THROMBOSIS;

ARTHRITIS, RHEUMATOID; BONE RESORPTION; CARTILAGE; CATHEPSINS; CLINICAL TRIALS; CYSTEINE PROTEINASE INHIBITORS; DRUG DESIGN; HUMANS; OSTEOARTHRITIS; OSTEOPOROSIS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 18944365919     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2004.12.013     Document Type: Review

References (171)

1. G.R. Mundy Osteoporosis: pathophysiology and non-pharmacological management Best Pract. Res., Clin. Rheumatol. 15 2001 727 745
2. E.P. Smith, J. Boyd, G.R. Frank, H. Takahashi, R.M. Cohen, B. Specker, T.C. Williams, D.B. Lubahn, and K.S. Korach Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man N. Engl. J. Med. 331 1994 1056 1061
3. E.F. Eriksen, M. Kassem, and B. Langdahl European and North American experience with HRT for the prevention of osteoporosis Bone 19 1996 179S 183S
4. L. Martin Rheumatoid arthritis: symptoms, diagnosis, and management Nurs. Times 100 2004 40 44
5. A.J. Silman, and J.E. Pearson Epidemiology and genetics of rheumatoid arthritis Arthritis Res. 4 Suppl. 3 2002 S265 S272
6. D.T. Felson, and T. Neogi Osteoarthritis: is it a disease of cartilage or of bone? Arthritis Rheum. 50 2004 341 344
7. I.F. Petersson, and L.T. Jacobsson Osteoarthritis of the peripheral joints Best Pract. Res., Clin. Rheumatol. 16 2002 741 760
8. G.A. Fitzgerald Coxibs and cardiovascular disease N. Engl. J. Med. 351 2004 1709 1711
9. D. Aletaha, and J.S. Smolen Dmard use in early rheumatoid arthritis. Lessons from observations in patients with established disease Clin. Exp. Rheumatol. 21 2003 S169 S173
10. P. Emery, and Y. Seto Role of biologics in early arthritis Clin. Exp. Rheumatol. 21 2003 S191 S194
11. R.H. Mullan, and B. Bresnihan Disease-modifying anti-rheumatic drug therapy and structural damage in early rheumatoid arthritis Clin. Exp. Rheumatol. 21 2003 S158 S164
12. J.M. Delaisse, and G. Vaes Mechanism of Mineral Solubilization and Matrix Degradation in Osteoclastic Bone Resorption 1992 CRC Press Boca Raton
13. B.D. Gelb, G.P. Shi, H.A. Chapman, and R.J. Desnick Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency Science 273 1996 1236 1238
14. J.M. Delaisse, M.T. Engsig, V. Everts, M. del Carmen Ovejero, M. Ferreras, L. Lund, T.H. Vu, Z. Werb, B. Winding, A. Lochter, M.A. Karsdal, T. Troen, T. Kirkegaard, T. Lenhard, A.M. Heegaard, L. Neff, R. Baron, and N.T. Foged Proteinases in bone resorption: obvious and less obvious roles Clin. Chim. Acta 291 2000 223 234
15. V. Everts, J.M. Delaisse, W. Korper, and W. Beertsen Cysteine proteinases and matrix metalloproteinases play distinct roles in the subosteoclastic resorption zone J. Bone Miner. Res. 13 1998 1420 1430
16. V. Everts, J.M. Delaisse, W. Korper, D.C. Jansen, W. Tigchelaar-Gutter, P. Saftig, and W. Beertsen The bone lining cell: its role in cleaning Howship's lacunae and initiating bone formation J. Bone Miner. Res. 17 2002 77 90
17. T.E. Hardingham, and A.J. Fosang Proteoglycans: many forms and many functions FASEB J. 6 1992 861 870
18. A.P. Hollander, T.F. Heathfield, C. Webber, Y. Iwata, R. Bourne, C. Rorabeck, and A.R. Poole Increased damage to type II collagen in osteoarthritic articular cartilage detected by a new immunoassay J. Clin. Invest. 93 1994 1722 1732
19. C. Brinckerhoff Joint destruction in arthritis: metalloproteinases in the spotlight Arthritis Rheum. 34 1991 1073 1075
20. J.L. Gordon, A.H. Drummond, and W.A. Galloway Metalloproteinase inhibitors as therapeutics Clin. Exp. Rheumatol. 11 1993 S91 S94
21. M.P. Vincenti, I.M. Clark, and C.E. Brinckerhoff Using inhibitors of metalloproteinases to treat arthritis. Easier said than done? Arthritis Rheum. 37 1994 1115 1126
22. K. Mentzel, and R. Brauer Matrix metalloproteinases, IL-6, and nitric oxide in rat antigen-induced arthritis Clin. Exp. Rheumatol. 16 1998 269 276
23. F. Moldovan, J.P. Pelletier, J. Hambor, J.M. Cloutier, and J. Martel-Pelletier Collagenase-3 (matrix metalloprotease 13) is preferentially localized in the deep layer of human arthritic cartilage in situ: in vitro mimicking effect by transforming growth factor beta Arthritis Rheum. 40 1997 1653 1661
24. M.L. Moss, S.L. Jin, M.E. Milla, D.M. Bickett, W. Burkhart, H.L. Carter, W.J. Chen, W.C. Clay, J.R. Didsbury, D. Hassler, C.R. Hoffman, T.A. Kost, M.H. Lambert, M.A. Leesnitzer, P. McCauley, G. McGeehan, J. Mitchell, M. Moyer, G. Pahel, W. Rocque, L.K. Overton, F. Schoenen, T. Seaton, J.L. Su, and J.D. Becherer Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha Nature 385 1997 733 736
25. R.A. Black, C.T. Rauch, C.J. Kozlosky, J.J. Peschon, J.L. Slack, M.F. Wolfson, B.J. Castner, K.L. Stocking, P. Reddy, S. Srinivasan, N. Nelson, N. Boiani, K.A. Schooley, M. Gerhart, R. Davis, J.N. Fitzner, R.S. Johnson, R.J. Paxton, C.J. March, and D.P. Cerretti A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells Nature 385 1997 729 733
26. J.C. Fernandes, J. Martel-Pelletier, and J.P. Pelletier The role of cytokines in osteoarthritis pathophysiology Biorheology 39 2002 237 246
27. M. Abe, K. Kawamoto, H. Okamoto, and N. Horiuchi Induction of collagenase-2 (matrix metalloproteinase-8) gene expression by interleukin-1beta in human gingival fibroblasts J. Periodontal Res. 36 2001 153 159
28. B.K. Pilcher, B.D. Sudbeck, J.A. Dumin, H.G. Welgus, and W.C. Parks Collagenase-1 and collagen in epidermal repair Arch. Dermatol. Res. 290 1998 S37 S46
29. M.C. Burleigh, A.J. Barrett, and G.S. Lazarus Cathepsin b1. A lysosomal enzyme that degrades native collagen Biochem. J. 137 1974 387 398
30. H. Kirschke, A.A. Kembhavi, P. Bohley, and A.J. Barrett Action of rat liver cathepsin l on collagen and other substrates Biochem. J. 201 1982 367 372
31. P. Garnero, O. Borel, I. Byrjalsen, M. Ferreras, F.H. Drake, M.S. McQueney, N.T. Foged, P.D. Delmas, and J.M. Delaisse The collagenolytic activity of cathepsin K is unique among mammalian proteinases J. Biol. Chem. 273 1998 32347 32352
32. W. Kafienah, D. Bromme, D.J. Buttle, L.J. Croucher, and A.P. Hollander Human cathepsin K cleaves native type I and II collagens at the N-terminal end of the triple helix Biochem. J. 331 1998 727 732
33. M. Morgelin, M. Paulsson, T.E. Hardingham, D. Heinegard, and J. Engel Cartilage proteoglycans. Assembly with hyaluronate and link protein as studied by electron microscopy Biochem. J. 253 1988 175 185
34. L.D. Kozaci, D.J. Buttle, and A.P. Hollander Degradation of type ii collagen, but not proteoglycan, correlates with matrix metalloproteinase activity in cartilage explant cultures Arthritis Rheum. 40 1997 164 174
35. M.W. Lark, E.K. Bayne, and L.S. Lohmander Aggrecan degradation in osteoarthritis and rheumatoid arthritis Acta Orthop. Scand., Suppl. 266 1995 92 97
36. M.D. Tortorella, T.C. Burn, M.A. Pratta, I. Abbaszade, J.M. Hollis, R. Liu, S.A. Rosenfeld, R.A. Copeland, C. Decicco, R. Wynn, A. Rockwell, F. Yang, J.L. Duke, K. Solomon, H. George, R. Bruckner, H. Nagase, Y. Itoh, D.M. Ellis, H. Ross, B.H. Wiswall, K. Murphy, M.C.J. Hillman, G.F. Hollis, and R.C. Newton Purification and cloning of aggrecanase-1: a member of the Adamts family of proteins Science 284 1999 1664 1666
37. I. Abbaszade, R.Q. Liu, F. Yang, S.A. Rosenfeld, O.H. Ross, J.R. Link, D.M. Ellis, M.D. Tortorella, M.A. Pratta, J.M. Hollis, R. Wynn, J.L. Duke, H.J. George, M.C. Hillman Jr., K. Murphy, B.H. Wiswall, R.A. Copeland, C.P. Decicco, R. Bruckner, H. Nagase, Y. Itoh, R.C. Newton, R.L. Magolda, J.M. Trzaskos, and T.C. Burn Cloning and characterization of adamts11, an aggrecanase from the Adamts family J. Biol. Chem. 274 1999 23443 23450
38. E.C. Arner, C.E. Hughes, C.P. Decicco, B. Caterson, and M.D. Tortorella Cytokine-induced cartilage proteoglycan degradation is mediated by aggrecanase Osteoarthr. Cartil. 6 1998 214 228
39. M.W. Lark, E.K. Bayne, J. Flanagan, C.F. Harper, L.A. Hoerrner, N.I. Hutchinson, I.I. Singer, S.A. Donatelli, J.R. Weidner, H.R. Williams, R.A. Mumford, and L.S. Lohmander Aggrecan degradation in human cartilage. Evidence for both matrix metalloproteinase and aggrecanase activity in normal, osteoarthritic, and rheumatoid joints J. Clin. Invest. 100 1997 93 106
40. J.S. Mort, M.C. Magny, and E.R. Lee Cathepsin b: an alternative protease for the generation of an aggrecan 'metalloproteinase' cleavage neoepitope Biochem. J. 335 1998 491 494
41. Q. Nguyen, J.S. Mort, and P.J. Roughley Cartilage proteoglycan aggregate is degraded more extensively by cathepsin L than by cathepsin B Biochem. J. 266 1990 569 573
42. Q. Nguyen, J. Liu, P.J. Roughley, and J.S. Mort Link protein as a monitor in situ of endogenous proteolysis in adult human articular cartilage Biochem. J. 278 1991 143 147
43. W.S. Hou, Z. Li, F.H. Buttner, E. Bartnik, and D. Bromme Cleavage site specificity of cathepsin K toward cartilage proteoglycans and protease complex formation Biol. Chem. 384 2003 891 897
44. F. Lecaille, J. Kaleta, and D. Bromme Human and parasitic papain-like cysteine proteases: their role in physiology and pathology and recent developments in inhibitor design Chem. Rev. 102 2002 4459 4488
45. I.M. Berquin, and B.F. Sloane Cysteine proteases and tumor progression Perspect. Drug Discov. Des. 2 1995 371 388
46. M.E. McGrath The lysosomal cysteine proteases Annu. Rev. Biophys. Biomol. Struct. 28 1999 181 204
47. V. Turk, B. Turk, and D. Turk Lysosomal cysteine proteases: facts and opportunities EMBO J. 20 2001 4629 4633
48. J.A. Villadangos, and H.L. Ploegh Proteolysis in MHC class II antigen presentation: who's in charge? Immunity 12 2000 233 239
49. K. Honey, and A.Y. Rudensky Lysosomal cysteine proteases regulate antigen presentation Nat. Rev., Immunol. 3 2003 472 482
50. D.S. Yamashita, and R.A. Dodds Cathepsin K and the design of inhibitors of cathepsin K Curr. Pharm. Des. 6 2000 1 24
51. T. Goto, T. Yamaza, and T. Tanaka Cathepsins in the osteoclast J. Electron Microsc. (Tokyo) 52 2003 551 558
52. J.A. Villadangos, R.A. Bryant, J. Deussing, C. Driessen, A.M. Lennon-Dumenil, R.J. Riese, W. Roth, P. Saftig, G.P. Shi, H.A. Chapman, C. Peters, and H.L. Ploegh Proteases involved in MHC class II antigen presentation Immunol. Rev. 172 1999 109 120
53. J. Deussing, W. Roth, P. Saftig, C. Peters, H.L. Ploegh, H.L. Ploegh, and J.A. Villadangos Cathepsins B and D are dispensable for major histocompatibility complex class II-mediated antigen presentation Proc. Natl. Acad. Sci. U. S. A. 95 1998 4516 4521
54. P. Cresswell Invariant chain structure and MHC class II function Cell 84 1996 505 507
55. R.J. Riese, P. Wolf, D. Bromme, L.R. Natkin, J.A. Villadangos, H.L. Ploegh, and H.A. Chapman Essential role for cathepsin S in MHC class II-associated invariant chain processing and peptide loading Immunity 4 1996 357 366
56. G.P. Shi, J.A. Villadangos, G. Dranoff, C. Small, L. Gu, K.J. Haley, R. Riese, H.L. Ploegh, and H.A. Chapman Cathepsin s required for normal MHC class II peptide loading and germinal center development Immunity 10 1999 197 206
57. T.Y. Nakagawa, W.H. Brissette, P.D. Lira, R.J. Griffiths, N. Petrushova, J. Stock, J.D. McNeish, S.E. Eastman, E.D. Howard, S.R. Clarke, E.F. Rosloniec, E.A. Elliott, and A.Y. Rudensky Impaired invariant chain degradation and antigen presentation and diminished collagen-induced arthritis in cathepsin S null mice Immunity 10 1999 207 217
58. R.J. Riese, R.N. Mitchell, J.A. Villadangos, G.P. Shi, J.T. Palmer, E.R. Karp, G.T. De Sanctis, H.L. Ploegh, and H.A. Chapman Cathepsin S activity regulates antigen presentation and immunity J. Clin. Invest. 101 1998 2351 2363
59. E. Tolosa, W. Li, Y. Yasuda, W. Wienhold, L.K. Denzin, A. Lautwein, C. Driessen, P. Schnorrer, E. Weber, S. Stevanovic, R. Kurek, A. Melms, and D. Bromme Cathepsin V is involved in the degradation of invariant chain in human thymus and is overexpressed in myasthenia gravis J. Clin. Invest. 112 2003 517 526
60. T. Nakagawa, W. Roth, P. Wong, A. Nelson, A. Farr, J. Deussing, J.A. Villadangos, H. Ploegh, C. Peters, and A.Y. Rudensky Cathepsin l: critical role in ii degradation and cd4 T cell selection in the thymus Science 280 1998 450 453
61. G.P. Shi, J.S. Munger, J.P. Meara, D.H. Rich, and H.A. Chapman Molecular cloning and expression of human alveolar macrophage cathepsin S, an elastinolytic cysteine protease J. Biol. Chem. 267 1992 7258 7262
62. G.P. Shi, R.A. Bryant, R. Riese, S. Verhelst, C. Driessen, Z. Li, D. Bromme, H.L. Ploegh, and H.A. Chapman Role for cathepsin F in invariant chain processing and major histocompatibility complex class II peptide loading by macrophages J. Exp. Med. 191 2000 1177 1186
63. A.R. Pettit, and R. Thomas Dendritic cells: the driving force behind autoimmunity in rheumatoid arthritis? Immunol. Cell Biol. 77 1999 420 427
64. H. Kirschke, I. Schmidt, and B. Wiederanders Cathepsin S. The cysteine proteinase from bovine lymphoid tissue is distinct from cathepsin l (ec 3.4.22.15) Biochem. J. 240 1986 455 459
65. D. Bromme, P.R. Bonneau, P. Lachance, B. Wiederanders, H. Kirschke, C. Peters, D.Y. Thomas, A.C. Storer, and T. Vernet Functional expression of human cathepsin S in Saccharomyces cerevisiae. Purification and characterization of the recombinant enzyme J. Biol. Chem. 268 1993 4832 4838
66. V.Y. Reddy, Q.Y. Zhang, and S.J. Weiss Pericellular mobilization of the tissue-destructive cysteine proteinases, cathepsins B, L, and S, by human monocyte-derived macrophages Proc. Natl. Acad. Sci. U. S. A. 92 1995 3849 3853
67. R.J. Wilkins, and A.C. Hall Control of matrix synthesis in isolated bovine chondrocytes by extracellular and intracellular pH J. Cell. Physiol. 164 1995 474 481
68. Y.T. Konttinen, J. Mandelin, T.F. Li, J. Salo, J. Lassus, M. Liljestrom, M. Hukkanen, M. Takagi, I. Virtanen, and S. Santavirta Acidic cysteine endoproteinase cathepsin K in the degeneration of the superficial articular hyaline cartilage in osteoarthritis Arthritis Rheum. 46 2002 953 960
69. H. Kirschke, A.J. Barrett, and N.D. Rawlings Proteinases 1: Lysosomal Cysteine Proteases vol. 2 1995 Academic Press London
70. D. Brömme, K. Okamoto, B.B. Wang, and S. Biroc Human cathepsin O2, a matrix protein-degrading cysteine protease expressed in osteoclasts. Functional expression of human cathepsin O2 in f and characterization of the enzyme J. Biol. Chem. 271 1996 2126 2132
71. G.K. Sukhova, Y. Zhang, J.H. Pan, Y. Wada, T. Yamamoto, M. Naito, T. Kodama, S. Tsimikas, J.L. Witztum, M.L. Lu, Y. Sakara, M.T. Chin, P. Libby, and G.P. Shi Deficiency of cathepsin S reduces atherosclerosis in LDL receptor-deficient mice J. Clin. Invest. 111 2003 897 906
72. W.-S. Hou, W. Li, G. Keyszer, E. Weber, R. Levy, M.J. Klein, E.M. Gravallese, S.R. Goldring, and D. Bromme Comparison of cathepsins K and S expression within the rheumatoid and osteoarthritic synovium Arthritis Rheum. 46 2002 663 674
73. D. Bromme, and K. Okamoto Human cathepsin O2, a novel cysteine protease highly expressed in osteoclastomas and ovary molecular cloning, sequencing and tissue distribution Biol. Chem. Hoppe-Seyler 376 1995 379 384
74. F. Bühling, A. Gerber, C. Häckel, S. Krüger, T. Köhnlein, D. Brömme, D. Reinhold, F. Ansorge, and T. Welte Expression of cathepsin K in lung epithelial cells Am. J. Respir. Crit. Care Med. 20 1999 612 619
75. C. Haeckel, S. Krueger, F. Buehling, D. Broemme, K. Franke, A. Schuetze, I. Roese, and A. Roessner Expression of cathepsin K in the human embryo and fetus Dev. Dyn. 216 1999 89 95
76. G.K. Sukhova, G. Shi, P.D.I. Simon, H.A. Chapman, and P. Libby Expression of the elastolytic cathepsins s and k in human atheroma and regulation of their production in smooth muscle cells J. Clin. Invest. 102 1998 576 583
77. W.S. Hou, Z. Li, R.E. Gordon, K. Chan, M.J. Klein, R. Levy, M. Keysser, G. Keyszer, and D. Bromme Cathepsin K is a critical protease in synovial fibroblast-mediated collagen degradation Am. J. Pathol. 159 2001 2167 2177
78. V. Everts, W. Beertsen, and R. Schroder Effects of proteinase inhibitors leupeptin and e-64 on osteoclastic bone resorption Calcif. Tissue Int. 43 1988 172 178
79. F.H. Drake, R.A. Dodds, I.E. James, J.R. Connor, C. Debouck, S. Richardson, E. Lee-Rykaczewski, L. Coleman, D. Rieman, R. Barthlow, G. Hastings, and M. Gowen Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoclasts J. Biol. Chem. 271 1996 12511 12516
80. K. Tezuka, Y. Tezuka, A. Maejima, T. Sato, K. Nemoto, H. Kamioka, Y. Hakeda, and M. Kumegawa Molecular cloning of a possible cysteine proteinase predominantly expressed in osteoclasts J. Biol. Chem. 269 1994 1106 1109
81. S.M. Krane, and L. Simon E. Rubenstein D.D. Federman Scientific American Medicine 1994 Scientific American, Inc. New York 1 26
82. V. Everts, D.C. Aronson, and W. Beertsen Phagocytosis of bone collagen by osteoclasts in two cases of pycnodysostosis Calcif. Tissue Int. 37 1985 25 31
83. V. Everts, W.S. Hou, X. Rialland, W. Tigchelaar, P. Saftig, D. Bromme, B.D. Gelb, and W. Beertsen Cathepsin K deficiency in pycnodysostosis results in accumulation of non-digested phagocytosed collagen in fibroblasts Calcif. Tissue Int. 73 2003 380 386
84. B.D. Gelb, D. Brömme, and R.J. Desnick C.R. Sriver A.L. Beaudet D. Valle W.C.S. Sly The Metabolic and Molecular Bases of Inherited Diseases 2001 McGraw-Hill. Inc New York 3453 3468
85. P. Saftig, O. Wehmeyer, E. Hunziker, S. Jones, A. Boyde, W. Rommerskirch, and K. von Figura Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin K-deficient mice Proc. Natl. Acad. Sci. U. S. A. 95 1998 13453 13458
86. R. Kiviranta, J. Morko, H. Uusitalo, H.T. Aro, E. Vuorio, and J. Rantakokko Accelerated turnover of metaphyseal trabecular bone in mice overexpressing cathepsin K J. Bone Miner. Res. 16 2001 1444 1452
87. I.E. James, R.W. Marquis, S.M. Blake, S.M. Hwang, C.J. Gress, Y. Ru, D. Zembryki, D.S. Yamashita, M.S. McQueney, T.A. Tomaszek, H.J. Oh, M. Gowen, D.F. Veber, and M.W. Lark Potent and selective cathepsin l inhibitors do not inhibit human osteoclast resorption in vitro J. Biol. Chem. 276 2001 11507 11511
88. W. Potts, J. Bowyer, H. Jones, D. Tucker, A.J. Freemont, A. Millest, C. Martin, W. Vernon, D. Neerunjun, G. Slynn, F. Harper, and R. Maciewicz Cathepsin L-deficient mice exhibit abnormal skin and bone development and show increased resistance to osteoporosis following ovariectomy Int. J. Exp. Pathol. 85 2004 85 96
89. Z. Li, W.S. Hou, C.R. Escalante-Torres, B.D. Gelb, and D. Bromme Collagenase activity of cathepsin K depends on complex formation with chondroitin sulfate J. Biol. Chem. 277 2002 28669 28676
90. Z. Li, W.S. Hou, and D. Bromme Collagenolytic activity of cathepsin K is specifically modulated by cartilage-resident chondroitin sulfates Biochemistry 39 2000 529 536
91. Z. Li, Y. Yasuda, W. Li, M. Bogyo, N. Katz, R.E. Gordon, G.B. Fields, and D. Bromme Regulation of collagenase activities of human cathepsins by glycosaminoglycans J. Biol. Chem. 279 2004 5470 5479
92. L. Polgar, and P. Halasz Current problems in mechanistic studies of serine and cysteine proteinases Biochem. J. 207 1982 1 10
93. R.E. Esser, R.A. Angelo, M.D. Murphey, L.M. Watts, L.P. Thornburg, J.T. Palmer, J.W. Talhouk, and R.E. Smith Cysteine proteinase inhibitors decrease articular cartilage and bone destruction in chronic inflammatory arthritis Arthritis Rheum. 37 1994 236 247
94. R.E. Esser, L.M. Watts, R.A. Angelo, L.P. Thornburg, J.J. Prior, and J.T. Palmer The effects of fluoromethyl ketone inhibitors of cathepsin B on adjuvant-induced arthritis J. Rheumatol. 20 1993 1176 1183
95. D. Wang, W. Li, M. Pechar, P. Kopečkova, D. Brömme, and J. Kopeček Cathepsin K inhibitor-polymer conjugates: potential drugs for the treatment of osteoporosis and rheumatoid arthritis Int. J. Pharm. 277 2004 73 79
96. D. Wang, M. Pechar, W. Li, P. Kopečkova, D. Brömme, and J. Kopeček Inhibition of cathepsin K with lysosomotropic macromolecular inhibitors Biochemistry 41 2002 8849 8859
97. V. Leroy, and S. Thurairatnam Cathepsin S inhibitors Expert Opin. Ther. Pat. 14 2004 301 311
98. D. Bromme, and J. Kaleta Thiol-dependent cathepsins: pathophysiological implications and recent advances in inhibitor design Curr. Pharm. Des. 8 2002 1639 1658
99. D.S. Yamashita, W.W. Smith, B. Zhao, C.A. Janson, T.A. Tomaszek, M.J. Bossard, M.A. Levy, H.-J. Oh, T.J. Carr, S.K. Thomson, C.F. Ijames, M. McQueney, K.J. D'Alessio, B.Y. Amegadzie, C.R. Hanning, S. Abdel-Meguid, R.L. Desjarlais, J.G. Gleason, and D.F. Veber Structure and design of potent and selective cathepsin K inhibitors J. Am. Chem. Soc. 119 1997 11351 11352
100. D. Leung, G. Abbenante, and D.P. Fairlie Protease inhibitors: current status and future prospects J. Med. Chem. 43 2000 305 341
101. H.H. Otto, and T. Schirmeister Cysteine proteases and their inhibitors Chem. Rev. 97 1997 133 171
102. S.K. Thompson, S.M. Halbert, M.J. Bossard, T.A. Tomaszek, M.A. Levy, B. Zhao, W.W. Smith, S.S. Abdel-Meguid, C.A. Janson, K.J. D'Alessio, M.S. McQueney, B.Y. Amegadzie, C.R. Hanning, R.L. DesJarlais, J. Briand, S.K. Sarkar, M.J. Huddleston, C.F. Ijames, S.A. Carr, K.T. Garnes, A. Shu, J.R. Heys, J. Bradbeer, D. Zembryski, and L. Lee-Rykaczewski Design of potent and selective human cathepsin K inhibitors that span the active site Proc. Natl. Acad. Sci. U. S. A. 94 1997 14249 14254
103. S.K. Thompson, W.W. Smith, B. Zhao, S.M. Halbert, T.A. Tomaszek, D.G. Tew, M.A. Levy, C.A. Janson, D.A. KJ, M.S. McQueney, J. Kurdyla, C.S. Jones, R.L. DesJarlais, S.S. Abdel-Meguid, and D.F. Veber Structure-based design of cathepsin K inhibitors containing a benzyloxy-substituted benzoyl peptidomimetic J. Med. Chem. 41 1998 3923 3927
104. R.W. Marquis, Y. Ru, S.M. LoCastro, J. Zeng, D.S. Yamashita, H.J. Oh, K.F. Erhard, L.D. Davis, T.A. Tomaszek, D. Tew, K. Salyers, J. Proksch, K. Ward, B. Smith, M. Levy, M.D. Cummings, R.C. Haltiwanger, G. Trescher, B. Wang, M.E. Hemling, C.J. Quinn, H.Y. Cheng, F. Lin, W.W. Smith, C.A. Janson, B. Zhao, M.S. McQueney, K. D'Alessio, C.P. Lee, A. Marzulli, R.A. Dodds, S. Blake, S.M. Hwang, I.E. James, C.J. Gress, B.R. Bradley, M.W. Lark, M. Gowen, and D.F. Veber Azepanone-based inhibitors of human and rat cathepsin K J. Med. Chem. 44 2001 1380 1395
105. R.W. Marquis, Y. Ru, D.S. Yamashita, H.J. Oh, J. Yen, S.K. Thompson, T.J. Carr, M.A. Levy, T.A. Tomaszek, C.F. Ijames, W.W. Smith, B. Zhao, C.A. Janson, S.S. Abdel-Meguid, K.J. D'Alessio, M.S. McQueney, and D.F. Veber Potent dipeptidylketone inhibitors of the cysteine protease cathepsin K Bioorg. Med. Chem. 7 1999 581 588
106. R.W. Marquis, Y. Ru, J. Zeng, R.E. Trout, S.M. LoCastro, A.D. Gribble, J. Witherington, A.E. Fenwick, B. Garnier, T. Tomaszek, D. Tew, M.E. Hemling, C.J. Quinn, W.W. Smith, B. Zhao, M.S. McQueney, C.A. Janson, K. D'Alessio, and D.F. Veber Cyclic ketone inhibitors of the cysteine protease cathepsin K J. Med. Chem. 44 2001 725 736
107. R.W. Marquis, D.S. Yamashita, L. Ru, S.M. Y, H.J. Oh, K.F. Erhard, R.L. DesJarlais, M.S. Head, W.W. Smith, B. Zhao, C.A. Janson, S.S. Abdel-Meguid, T.A. Tomaszek, M.A. Levy, and D.F. Veber Conformationally constrained 1,3-diamino ketones: a series of potent inhibitors of the cysteine protease cathepsin K J. Med. Chem. 41 1998 3563 3567
108. M.W. Lark, G.B. Stroup, I.E. James, R.A. Dodds, S.M. Hwang, S.M. Blake, B.A. Lechowska, S.J. Hoffman, B.R. Smith, R. Kapadia, X. Liang, K. Erhard, Y. Ru, X. Dong, R.W. Marquis, D. Veber, and M. Gowen A potent small molecule, nonpeptide inhibitor of cathepsin K (sb 331750) prevents bone matrix resorption in the ovariectomized rat Bone 30 2002 746 753
109. F.X. Tavares, V. Boncek, D.N. Deaton, A.M. Hassell, S.T. Long, A.B. Miller, A.A. Payne, L.R. Miller, L.M. Shewchuk, K. Wells-Knecht, D.H. Willard Jr., L.L. Wright, and H.Q. Zhou Design of potent, selective, and orally bioavailable inhibitors of cysteine protease cathepsin K J. Med. Chem. 47 2004 588 599
110. D.S. Yamashita, R. Xie, H. Lin, B. Wang, S.D. Shi, C.J. Quinn, M.E. Hemling, C. Hissong, T.A. Tomaszek, and D.F. Veber Benzodioxocin-3-ones and n-acyl-3-amino-3-buten-2-ones: novel classes of cathepsin K cysteine protease inhibitors J. Pept. Res. 63 2004 265 269
111. F.X. Tavares, D.N. Deaton, A.B. Miller, L.R. Miller, L.L. Wright, and H.Q. Zhou Potent and selective ketoamide-based inhibitors of cysteine protease, cathepsin K J. Med. Chem. 47 2004 5049 5056
112. F.X. Tavares, D.N. Deaton, L.R. Miller, and L.L. Wright Ketoamide-based inhibitors of cysteine protease, cathepsin K: P3 modifications J. Med. Chem. 47 2004 5057 5068
113. G.B. Stroup, M.W. Lark, D.F. Veber, A. Bhattacharyya, S. Blake, L.C. Dare, K.F. Erhard, S.J. Hoffman, I.E. James, R.W. Marquis, Y. Ru, J.A. Vasko-Moser, B.R. Smith, T. Tomaszek, and M. Gowen Potent and selective inhibition of human cathepsin K leads to inhibition of bone resorption in vivo in a nonhuman primate J. Bone Miner. Res. 16 2001 1739 1746
114. J. Robichaud, C. Bayly, R. Oballa, P. Prasit, C. Mellon, J.P. Falgueyret, M.D. Percival, G. Wesolowski, and S.B. Rodan Rational design of potent and selective NH-linked aryl/heteroaryl cathepsin K inhibitors Bioorg. Med. Chem. Lett. 14 2004 4291 4295
115. J. Robichaud, R. Oballa, P. Prasit, J.P. Falgueyret, M.D. Percival, G. Wesolowski, S.B. Rodan, D. Kimmel, C. Johnson, C. Bryant, S. Venkatraman, E. Setti, R. Mendonca, and J.T. Palmer A novel class of nonpeptidic biaryl inhibitors of human cathepsin K J. Med. Chem. 46 2003 3709 3727
116. M. Quibell, S. Taylor, Medivir UK Ltd/peptimmune US, EP 1 413 580 A1 (2004).
117. C.L. Cywin, R.A. Firestone, D.W. McNeil, C.A. Grygon, K.M. Crane, D.M. White, P.R. Kinkade, J.L. Hopkins, W. Davidson, M.E. Labadia, J. Wildeson, M.M. Morelock, J.D. Peterson, E.L. Raymond, M.L. Brown, and D.M. Spero The design of potent hydrazones and disulfides as cathepsin S inhibitors Bioorg. Med. Chem. 11 2003 733 740
118. Y.D. Ward, D.S. Thomson, L.L. Frye, C.L. Cywin, T. Morwick, M.J. Emmanuel, R. Zindell, D. McNeil, Y. Bekkali, M. Girardot, M. Hrapchak, M. DeTuri, K. Crane, D. White, S. Pav, Y. Wang, M.H. Hao, C.A. Grygon, M.E. Labadia, D.M. Freeman, W. Davidson, J.L. Hopkins, M.L. Brown, D.M. Spero, and M. Giradot Design and synthesis of dipeptide nitriles as reversible and potent cathepsin S inhibitors J. Med. Chem. 45 2002 5471 5482
119. S.B. Cohen An update on bisphosphonates Curr. Rheumatol. Rep. 6 2004 59 65
120. K.G. Saag, R. Emkey, T.J. Schnitzer, J.P. Brown, F. Hawkins, S. Goemaere, G. Thamsborg, U.A. Liberman, P.D. Delmas, M.P. Malice, M. Czachur, and A.G. Daifotis Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-induced osteoporosis intervention study group N. Engl. J. Med. 339 1998 292 299
121. E.M. Umland, C. Rinaldi, S.M. Parks, and E.G. Boyce The impact of estrogen replacement therapy and raloxifene on osteoporosis, cardiovascular disease, and gynecologic cancers Ann. Pharmacother. 33 1999 1315 1328
122. I.R. Reid The roles of calcium and vitamin d in the prevention of osteoporosis Endocrinol. Metab. Clin. N. Am. 27 1998 389 398
123. A. Cranney, P. Tugwell, N. Zytaruk, V. Robinson, B. Weaver, B. Shea, G. Wells, J. Adachi, L. Waldegger, and G. Guyatt Meta-analyses of therapies for postmenopausal osteoporosis: VI. Meta-analysis of calcitonin for the treatment of postmenopausal osteoporosis Endocr. Rev. 23 2002 540 551
124. R.M. Neer, C.D. Arnaud, J.R. Zanchetta, R. Prince, G.A. Gaich, J.Y. Reginster, A.B. Hodsman, E.F. Eriksen, S. Ish-Shalom, H.K. Genant, O. Wang, and B.H. Mitlak Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis N. Engl. J. Med. 344 2001 1434 1441
125. E.S. Chan, and B.N. Cronstein Molecular action of methotrexate in inflammatory diseases Arthritis Res. 4 2002 266 273
126. V.A. Danis, A.J. Kulesz, D.S. Nelson, and P.M. Brooks The effect of gold sodium thiomalate and auranofin on lipopolysaccharide-induced interleukin-1 production by blood monocytes in vitro: variation in healthy subjects and patients with arthritis Clin. Exp. Immunol. 79 1990 335 340
127. J. Zou, M. Rudwaleit, J. Brandt, A. Thiel, J. Braun, and J. Sieper Down-regulation of the nonspecific and antigen-specific T cell cytokine response in ankylosing spondylitis during treatment with infliximab Arthritis Rheum. 48 2003 780 790
128. A. Prakash, and B. Jarvis Leflunomide: a review of its use in active rheumatoid arthritis Drugs 58 1999 1137 1164
129. F.C. Breedveld, and J.M. Dayer Leflunomide: mode of action in the treatment of rheumatoid arthritis Ann. Rheum. Dis. 59 2000 841 849
130. B. Kaminska, K. Gaweda-Walerych, and M. Zawadzka Molecular mechanisms of neuroprotective action of immunosuppressants-facts and hypotheses J. Cell. Mol. Med. 8 2004 45 58
131. P. Gadangi, M. Longaker, D. Naime, R.I. Levin, P.A. Recht, M.C. Montesinos, M.T. Buckley, G. Carlin, and B.N. Cronstein The anti-inflammatory mechanism of sulfasalazine is related to adenosine release at inflamed sites J. Immunol. 156 1996 1937 1941
132. T. Matsubara, and K. Hirohata Suppression of human fibroblast proliferation by d-penicillamine and copper sulfate in vitro Arthritis Rheum. 31 1988 964 972
133. B.M. Frey Mechanism of action of immunosuppressive agents Ther. Umsch. 50 1993 71 76
134. R.I. Fox Mechanism of action of hydroxychloroquine as an antirheumatic drug Semin. Arthritis Rheum. 23 1993 82 91
135. J.R. Vane, and R.M. Botting The mechanism of action of aspirin Thromb. Res. 110 2003 255 258
136. M. Osiri, and L.W. Moreland Specific cyclooxygenase 2 inhibitors: a new choice of nonsteroidal anti-inflammatory drug therapy Arthritis Care Res. 12 1999 351 362
137. S.B. Abramson Et tu, acetaminophen? Arthritis Rheum. 46 2002 2831 2835
138. K. Saegusa, N. Ishimaru, K. Yanagi, R. Arakaki, K. Ogawa, I. Saito, N. Katunuma, and Y. Hayashi Cathepsin S inhibitor prevents autoantigen presentation and autoimmunity J. Clin. Invest. 110 2002 361 369
139. N. Katunuma, E. Murata, H. Kakegawa, A. Matsui, H. Tsuzuki, H. Tsuge, D. Turk, V. Turk, M. Fukushima, Y. Tada, and T. Asao Structure based development of novel specific inhibitors for cathepsin L and cathepsin S in vitro and in vivo FEBS Lett. 458 1999 6 10
140. T. Yasuma, S. Oi, N. Choh, T. Nomura, N. Furuyama, A. Nishimura, Y. Fujisawa, and T. Sohda Synthesis of peptide aldehyde derivatives as selective inhibitors of human cathepsin L and their inhibitory effect on bone resorption J. Med. Chem. 41 1998 4301 4308
141. N. Katunuma, A. Matsui, T. Inubushi, E. Murata, H. Kakegawa, Y. Ohba, D. Turk, V. Turk, Y. Tada, and T. Asao Structure-based development of pyridoxal propionate derivatives as specific inhibitors of cathepsin K in vitro and in vivo Biochem. Biophys. Res. Commun. 267 2000 850 854
142. K.J. Duffy, L.H. Ridgers, R.L. DesJarlais, T.A. Tomaszek, M.J. Bossard, S.K. Thompson, R.M. Keenan, and D.F. Veber Design and synthesis of diaminopyrrolidinone inhibitors of human osteoclast cathepsin K Bioorg. Med. Chem. Lett. 9 1999 1907 1910
143. E. Altmann, J. Renaud, J. Green, D. Farley, B. Cutting, and W. Jahnke Arylaminoethyl amides as novel non-covalent cathepsin K inhibitors J. Med. Chem. 45 2002 2352 2354
144. P.D. Greenspan, K.L. Clark, R.A. Tommasi, S.D. Cowen, L.W. McQuire, D.L. Farley, J.H. van Duzer, R.L. Goldberg, H. Zhou, Z. Du, J.J. Fitt, D.E. Coppa, Z. Fang, W. Macchia, L. Zhu, M.P. Capparelli, R. Goldstein, A.M. Wigg, J.R. Doughty, R.S. Bohacek, and A.K. Knap Identification of dipeptidyl nitriles as potent and selective inhibitors of cathepsin b through structure-based drug design J. Med. Chem. 44 2001 4524 4534
145. Novartis, Wo 01/58886 (2001).
146. BoehringerIngelheim, WO 02/20485 (2002).
147. BoehringerIngelheim, WO 01/09110 (2001).
148. BoehringerIngelheim, WO 01/19816 (2001).
149. J.P. Falgueyret, R.M. Oballa, O. Okamoto, G. Wesolowski, Y. Aubin, R.M. Rydzewski, P. Prasit, D. Riendeau, S.B. Rodan, and M.D. Percival Novel, nonpeptidic cyanamides as potent and reversible inhibitors of human cathepsins K and L J. Med. Chem. 44 2001 94 104
150. N.E. Zhou, J. Kaleta, E. Purisima, R. Menard, R.G. Micetich, and R. Singh 6-Acylamino-penam derivatives: Synthesis and inhibition of cathepsins B, L, K, and S Bioorg. Med. Chem. Lett. 12 2002 3417 3419
151. R. Singh, N.E. Zhou, D. Guo, A. Cameron, J. Kaleta, E. Purisima, R. Menard, R.G. Micetich, 6-substituted amino-4-oxa-1-azabicyclo 3,2,0 heptan-t-one derivatives as cysteine protease inhibitors, US 5,905,076 (1999).
152. R. Singh, N.E. Zhou, D. Guo, R.G. Micetich, Naeja pharmaceutical Inc, US 6,232,305 B1 (2001).
153. N.E. Zhou, D. Guo, G. Thomas, A.V. Reddy, J. Kaleta, E. Purisima, R. Menard, R.G. Micetich, and R. Singh 3-Acylamino-azetidin-2-one as a novel class of cysteine proteases inhibitors Bioorg. Med. Chem. Lett. 13 2003 139 141
154. R. Singh, N.E. Zhou, D. Guo, R.G. Micetich, Synphar laboratories Inc, US 05986108 (1999).
155. R. Singh, N.E. Zhou, A.V. Reddy, D.Y. Thomas, Q. Ding, J. Kaleta, R.G. Micetich, M. Whittaker, Cysteine protease inhibitors, US 6,635,621 (2003).
156. R.L. Thurmond, S. Sun, C.A. Sehon, S.M. Baker, H. Cai, Y. Gu, W. Jiang, J.P. Riley, K.N. Williams, J.P. Edwards, and L. Karlsson Identification of a potent and selective noncovalent cathepsin S inhibitor J. Pharmacol. Exp. Ther. 308 2004 268 276
157. R.L. Thurmond, M.P. Beavers, H. Cai, S.P. Meduna, D.J. Gustin, S. Sun, H.J. Almond, L. Karlsson, and J.P. Edwards Nonpeptidic, noncovalent inhibitors of the cysteine protease cathepsin S J. Med. Chem. 47 2004 4799 4801
158. N. Katunuma, H. Tsuge, M. Nukatsuka, T. Asao, and M. Fukushima Structure-based design of specific cathepsin inhibitors and their application to protection of bone metastases of cancer cells Arch. Biochem. Biophys. 397 2002 305 311
159. J.T. Palmer, D. Rasnick, J.L. Klaus, and D. Brömme Vinyl sulfones as mechanism-based cysteine protease inhibitors J. Med. Chem. 38 1995 3193 3196
160. D. Brömme, J.L. Klaus, K. Okamoto, D. Rasnick, and J.T. Palmer Peptidyl vinyl sulphones: a new class of potent and selective cysteine protease inhibitors: S2p2 specificity of human cathepsin O2 in comparison with cathepsins S and L Biochem. J. 315 1996 85 89
161. J.H. McKerrow, J.C. Engel, and C.R. Caffrey Cysteine protease inhibitors as chemotherapy for parasitic infections Bioorg. Med. Chem. 7 1999 639 644
162. D. Bromme, A. Schierhorn, H. Kirschke, B. Wiederanders, A. Barth, S. Fittkau, and H.U. Demuth Potent and selective inactivation of cysteine proteinases with n-peptidyl-o-acyl hydroxylamines Biochem. J. 263 1989 861 866
163. D. Bromme, and H.U. Demuth N,o-diacyl hydroxamates as selective and irreversible inhibitors of cysteine proteinases Methods Enzymol. 244 1994 671 685
164. L. Huang, A. Lee, and J.A. Ellman Identification of potent and selective mechanism-based inhibitors of the cysteine protease cruzain using solid-phase parallel synthesis J. Med. Chem. 45 2002 676 684
165. E. Shaw Peptidyl diazomethanes as inhibitors of cysteine and serine proteinases Methods Enzymol. 244 1994 649 656
166. A. Krantz A.J. Barrett Methods Enzymol. vol. 244 1994 Academic Press New York 656 671
167. R.A. Smith, A. Bhargava, C. Browe, J. Chen, J. Dumas, H. Hatoum-Mokdad, and R. Romero Discovery and parallel synthesis of a new class of cathepsin K inhibitors Bioorg. Med. Chem. Lett. 11 2001 2951 2954
168. D.M. Seyfried, R. Veyna, Y. Han, K. Li, N. Tang, R.L. Betts, S. Weinsheimer, M. Chopp, and J. Anagli A selective cysteine protease inhibitor is non-toxic and cerebroprotective in rats undergoing transient middle cerebral artery ischemia Brain Res. 901 2001 94 101
169. N.E. Zhou, A.V. Reddy, J. Kaleta, R.G. Micetich, and R. Singh Part ii. Synthesis and evaluation of 3-substituted-4-oxa-1-azabicyclo[3.2.0]heptan-7-ones as cysteine protease inhibitors Arkivoc VI 2001 116 121
170. R. Singh, N.E. Zhou, D. Guo, J. Kaleta, R.G. Micetich, Synphar laboratories Inc, US 5,925, 633 A (1999).
171. M.D. Melo, and G. Obeid Osteonecrosis of the maxilla in a patient with a history of bisphosphonate therapy J. Can. Dent. Assoc. 71 2005 111 113